Suppr超能文献

接受介入治疗的ST段抬高型心肌梗死患者院内死亡的预测因素。RO-STEMI注册研究数据分析

Predictors of in-Hospital Mortality of ST-Segment Elevation Myocardial Infarction Patients Undergoing Interventional Treatment. An Analysis of Data from the RO-STEMI Registry.

作者信息

Cretu Diana E, Udroiu Cristian A, Stoicescu Claudiu I, Tatu-Chitoiu Gabriel, Vinereanu Dragos

机构信息

Emergency University Hospital, Bucharest, Romania.

"Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.

出版信息

Maedica (Bucur). 2015 Sep;10(4):295-303.

Abstract

BACKGROUND

ST-segment elevation myocardial infarction (STEMI) remains a leading cause of morbidity and mortality worldwide. Primary percutaneous coronary intervention (pPCI) is the preferred therapy for STEMI if it is done within 120 min from the first medical contact, by an experienced team in a high-volume center. The aim of this study was to assess the clinical characteristics and predictors of in-hospital mortality of patients with STEMI treated by percutaneous coronary interventions (PCIs).

METHODS

We analyzed data from 15,076 STEMI patients enrolled in the RO-STEMI registry (ROmanian ST-Elevation Myocardial Infarction registry). Patients were divided into 2 groups: PCI (11.669; 77%) and conservative treated (3.407; 23%). PCI group includes both pPCI treated patients (84.3%), and patients undergoing rescue PCI (6.4%) and late PCI (9.3%).

RESULTS

The mean age of STEMI patients was 62.7+/-12.7 years. 70% were males. Patients treated by PCI were younger (61.4+/-12.2 versus 67.2+/-13.3, p< 0.0001) and more often men (80% versus 71%, p< 0.0001). They were less likely to have acute heart failure (Killip class II-IV) at admission (p< 0.0001). During admission, patients treated by PCI received more often dual antiplatelet therapy (97.6% versus 90.8%, p< 0.0001), statins (96.3% versus 87.5%, p< 0.0001), beta-blockers (83.8% versus 73.2%, p< 0.0001), and RAAS blockers (82.6% versus 66.4%, p< 0.0001). Overall in-hospital mortality was 7.1%: 4.1% in the PCI group and 15.7% in the conservative treated group. Multivariate analysis showed that, after adjusting for all clinical variables, Killip class II-IV at admission (OR: 9.2; 95%CI: 6.2-13.6; p< 0.0001), LVEF< 35% (OR: 3.8; 95%CI: 2.6-5.4; p< 0.0001), age older than 65 years (OR: 2.2; 95%CI: 1.5-3.2; p< 0.0001), and anterior location of myocardial infarction (OR: 2.1; 95% CI: 1.5-3; p< 0.0001) remained independent predictors for in-hospital mortality for STEMI patients treated interventionally.

CONCLUSION

Advanced Killip class, depressed LVEF, advanced age, and anterior location were the most powerful independent predictors of in-hospital mortality in STEMI patients who underwent interventional treatment.

摘要

背景

ST段抬高型心肌梗死(STEMI)仍是全球发病和死亡的主要原因。如果能在首次医疗接触后的120分钟内,由经验丰富的团队在大容量中心进行,直接经皮冠状动脉介入治疗(pPCI)是STEMI的首选治疗方法。本研究的目的是评估接受经皮冠状动脉介入治疗(PCI)的STEMI患者的临床特征和院内死亡的预测因素。

方法

我们分析了纳入RO-STEMI注册研究(罗马尼亚ST段抬高型心肌梗死注册研究)的15076例STEMI患者的数据。患者分为两组:PCI组(11669例;77%)和保守治疗组(3407例;23%)。PCI组包括接受pPCI治疗的患者(84.3%)、接受补救性PCI的患者(6.4%)和延迟PCI的患者(9.3%)。

结果

STEMI患者的平均年龄为62.7±12.7岁。70%为男性。接受PCI治疗的患者更年轻(61.4±12.2岁对67.2±13.3岁,p<0.0001),男性比例更高(80%对71%,p<0.0001)。他们入院时发生急性心力衰竭(Killip分级II-IV级)的可能性较小(p<0.0001)。在住院期间,接受PCI治疗的患者更常接受双联抗血小板治疗(97.6%对90.8%,p<0.0001)、他汀类药物(96.3%对87.5%,p<0.0001)、β受体阻滞剂(83.8%对73.2%,p<0.0001)和RAAS阻滞剂(82.6%对66.4%,p<0.0001)。总体院内死亡率为7.1%:PCI组为4.1%,保守治疗组为15.7%。多变量分析显示,在对所有临床变量进行校正后,入院时Killip分级II-IV级(OR:9.2;95%CI:6.2-13.6;p<0.0001)、左心室射血分数(LVEF)<35%(OR:3.8;95%CI:2.6-5.4;p<0.0001)、年龄大于65岁(OR:2.2;95%CI:1.5-3.2;p<0.0001)以及心肌梗死的前壁部位(OR:2.1;95%CI:1.5-3;p<0.0001)仍然是接受介入治疗的STEMI患者院内死亡的独立预测因素。

结论

Killip分级较高、LVEF降低、高龄和前壁部位是接受介入治疗的STEMI患者院内死亡最有力的独立预测因素。

相似文献

引用本文的文献

3
Sex Disparities in Ischemic Heart Disease Mortality in Europe.欧洲缺血性心脏病死亡率的性别差异。
JACC Adv. 2024 Sep 2;3(12):101252. doi: 10.1016/j.jacadv.2024.101252. eCollection 2024 Dec.

本文引用的文献

10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验